Physician profile
Ryyan Hyder
NPI 1053730895
$494.12
in general payments reported to CMS, 2019-2025
13 companies · $21.60 in 2025
The $21.60 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $187 · 2023: $85.91 · 2025: $21.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $133.89 | 2021 | |
| Medtronic, INC. | $122.37 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $54.40 | 2022-2023 | Farxiga, Lokelma |
| Amgen INC. | $23.30 | 2021 | |
| Amag Pharmaceuticals, INC. | $23.18 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.60 | 2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $19.88 | 2023 | Lupkynis |
| Akebia Therapeutics INC | $19.33 | 2021 | |
| Calliditas Therapeutics US INC. | $19.24 | 2022 | |
| Mallinckrodt Hospital Products INC. | $19.12 | 2023 | Acthar |
| Opko Pharmaceuticals, LLC | $15.74 | 2022 | |
| Pharmacosmos Therapeutics INC. | $14.81 | 2022 | |
| Travere Therapeutics, INC. | $7.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryyan Hyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.